查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800967

2025-2033年骨質疏鬆症藥物市場報告（依產品類型、給藥途徑及地區）

Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2024年全球骨質疏鬆症藥物市場規模達173億美元。展望未來， IMARC Group預計到2033年市場規模將達到250億美元，2025-2033年期間的成長率（CAGR）為3.98%。

骨質疏鬆症是一種會導致骨組織和骨強度下降的疾病。診斷方法包括X光、電腦斷層掃描（CT）和磁振造影（MRI）。目前市面上有各種不同劑型的藥物，從一般藥片到靜脈注射劑，用於緩解骨質疏鬆症的症狀。這些藥物有助於恢復骨吸收和骨形成的平衡，修復骨骼的微觀缺陷，降低骨折風險，並增強患者的整體肌肉力量。

由於久坐不動的生活方式、過度飲酒和吸煙增多，骨質疏鬆症的盛行率不斷上升，這是推動市場成長的關鍵因素。患有乳糜瀉、腎臟病或肝病、癌症、紅斑性狼瘡、多發性骨髓瘤和類風濕性關節炎的人數不斷增加，進一步加速了市場的成長。此外，骨量流失會隨著年齡的成長而增加，這增加了老年人骨質疏鬆症的風險。因此，老年人口的成長對全球骨質疏鬆症藥物的需求產生了積極影響。此外，一些管理機構正在開發新型療法，這也促進了市場的成長。例如，美國食品藥物管理局 (FDA) 已批准用於治療骨折風險高或對其他骨質疏鬆症療法不耐受的停經後女性的新型骨質疏鬆症藥物。此外，預計大量處於後期臨床試驗階段的藥物將在未來幾年推動市場成長。

本報告回答的關鍵問題

  • 全球骨質疏鬆症藥物市場有多大？ 2025-2033年全球骨質疏鬆症藥物市場的預期成長率為何？
  • 推動全球骨質疏鬆症藥物市場發展的關鍵因素有哪些？
  • COVID-19 對全球骨質疏鬆症藥物市場有何影響？
  • 根據產品類型，全球骨質疏鬆症藥物市場是如何分佈的？
  • 根據給藥途徑，全球骨質疏鬆症藥物市場如何分佈？
  • 全球骨質疏鬆症藥物市場的主要區域有哪些？
  • 全球骨質疏鬆症藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球骨質疏鬆症藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依產品類型

  • 雙磷酸鹽
  • 降鈣素
  • Rank 配體抑制劑
  • 副甲狀腺素治療（PTH）
  • 選擇性雌激素受體調節劑 (SERM)
  • 硬化蛋白抑制劑
  • 其他

第7章：市場區隔：依行政途徑

  • 口服
  • 注射劑
  • 其他

第8章：市場區隔：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章：SWOT分析

第 10 章：價值鏈分析

第 11 章：波特五力分析

第 12 章：價格分析

第 13 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Radius Health Inc.
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
Product Code: SR112025A3104

The global osteoporosis drugs market size reached USD 17.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.0 Billion by 2033, exhibiting a growth rate (CAGR) of 3.98% during 2025-2033.

Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.

The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.

Key Market Segmentation:

Breakup by Product Type:

  • Bisphosphonates
  • Calcitonin
  • Rank Ligand Inhibitor
  • Parathyroid Hormone Therapy (PTH)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Sclerostin Inhibitor
  • Others

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report

  • 1.How big is the global osteoporosis drugs market?
  • 2.What is the expected growth rate of the global osteoporosis drugs market during 2025-2033?
  • 3.What are the key factors driving the global osteoporosis drugs market?
  • 4.What has been the impact of COVID-19 on the global osteoporosis drugs market?
  • 5.What is the breakup of the global osteoporosis drugs market based on the product type?
  • 6.What is the breakup of the global osteoporosis drugs market based on the route of administration?
  • 7.What are the key regions in the global osteoporosis drugs market?
  • 8.Who are the key players/companies in the global osteoporosis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Osteoporosis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Bisphosphonates
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Calcitonin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rank Ligand Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Parathyroid Hormone Therapy (PTH)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Selective Estrogen Receptor Modulators (SERMs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Sclerostin Inhibitor
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Eli Lilly and Company
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 F. Hoffmann-La Roche AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 SWOT Analysis
    • 13.3.4 GlaxoSmithKline Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Merck & Co. Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Novartis AG
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Pfizer Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Radius Health Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Teva Pharmaceutical Industries Ltd.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 UCB S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Osteoporosis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Osteoporosis Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Osteoporosis Drugs Market: Breakup by Product Type (in %), 2024
  • Figure 4: Global: Osteoporosis Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 5: Global: Osteoporosis Drugs Market: Breakup by Region (in %), 2024
  • Figure 6: Global: Osteoporosis Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 7: Global: Osteoporosis Drugs (Bisphosphonates) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Osteoporosis Drugs (Bisphosphonates) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Osteoporosis Drugs (Calcitonin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Osteoporosis Drugs (Calcitonin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Osteoporosis Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Osteoporosis Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Osteoporosis Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Osteoporosis Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: North America: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: North America: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: United States: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: United States: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Canada: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Canada: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Asia-Pacific: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Asia-Pacific: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: China: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: China: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Japan: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Japan: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: India: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: India: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: South Korea: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: South Korea: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Australia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Australia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Indonesia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Indonesia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Europe: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Europe: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Germany: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Germany: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: France: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: France: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: United Kingdom: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: United Kingdom: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Italy: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Italy: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Spain: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Spain: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Russia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Russia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Latin America: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Latin America: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Brazil: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Brazil: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Mexico: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Mexico: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Middle East and Africa: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Middle East and Africa: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Osteoporosis Drugs Market: Breakup by Country (in %), 2024
  • Figure 76: Global: Osteoporosis Drugs Industry: SWOT Analysis
  • Figure 77: Global: Osteoporosis Drugs Industry: Value Chain Analysis
  • Figure 78: Global: Osteoporosis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Osteoporosis Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Osteoporosis Drugs Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 3: Global: Osteoporosis Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Osteoporosis Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Osteoporosis Drugs Market: Competitive Structure
  • Table 6: Global: Osteoporosis Drugs Market: Key Players